While advances in disease-modifying therapies have reduced inflammatory relapses in MS patients, many still experience progressive disability due to neurodegeneration. We are particularly interested in how this progressive degeneration occurs in the context of seemingly well-treated relapsing MS.
Our lab employs magnetic resonance imaging (MRI) and positron emission tomography (PET) to investigate the pathological drivers of tissue damage and disability in MS. We aim to understand how unrecognized or under-treated aspects of MS contribute to symptoms, clinical worsening, and neurodegeneration. Our ultimate goal is to uncover how MS affects the brain and spine, in the hopes of identifying new therapeutic avenues for patients.
